MK-8723 + Matching Placebo

Phase 1Completed

2 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Immune Thrombocytopenia Purpura

Conditions

Immune Thrombocytopenia Purpura

Trial Timeline

Oct 31, 2013 → Apr 26, 2015

NCT ID

NCT01963260

About MK-8723 + Matching Placebo

MK-8723 + Matching Placebo is a phase 1 stage product being developed by Merck for Immune Thrombocytopenia Purpura. The current trial status is completed. This product is registered under clinical trial identifier NCT01963260. Target conditions include Immune Thrombocytopenia Purpura.

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenia Purpura were approved

Approved (7) Terminated (2) Active (13)

✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved

✅IgPro10CSLApproved

✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved

✅Methylprednisolone + PrednisoloneBiogenApproved

✅Flebogamma 5% DIFGrifolsApproved

✅Asceniv™ADMA BiologicsApproved

✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01963260	Phase 1	Completed	Oct 31, 2013	Apr 26, 2015	Immune Thrombocytopenia Purpura

Competing Products

20 competing products in Immune Thrombocytopenia Purpura

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Placebo	Eli Lilly	Phase 1/2	39
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	17
Satralizumab	Chugai Pharmaceutical	Phase 3	47
Placebo + Lusutrombopag	Shionogi	Phase 2	27
Lusutrombopag	Shionogi	Phase 2	27
Romiplostim	Kyowa Kirin	Phase 1/2	32
AMG 531	Kyowa Kirin	Phase 2/3	38
Romiplostim + Placebo	Kyowa Kirin	Phase 3	40
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	35
Romiplostim and danazol	Kyowa Kirin	Phase 2	31
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	29
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	29
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	40
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	35
Herombopag	Jiangsu Hengrui Medicine	Phase 3	36
Zostavax®	Merck	Pre-clinical	18
Raltegravir + Atazanavir	Merck	Pre-clinical	26
Zostavax	Merck	Pre-clinical	26
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM	Novartis	Phase 2	35